



**BABY NUTRITION. REIMAGINED.**

**INVESTOR PRESENTATION  
SEPTEMBER 2020**

# DISCLAIMER

This confidential presentation of Else Nutrition Holdings Inc. ("Else") is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This confidential presentation is not, and under no circumstances is to be construed as, a prospectus, advertisement or prospectus offering of securities. This confidential presentation is for the confidential use of only those persons to whom it is transmitted or provided by Else. By their acceptance of this confidential presentation, recipients agree that they will not transmit, reproduce or make available to any person, other than to their professional advisors, this confidential presentation or any of the information contained herein.

## CAUTION REGARDING FORWARD LOOKING STATEMENTS

Certain information included in this confidential presentation, including any information as to future financial or operating performance and other statements that express expectations or estimates of future performance, constitute "forward-looking statements". Forward-looking statements can be identified by words such as: "will be", "forecast", "future", "beyond", "potential", "planned" "will" or variations of such words and phrases or similar references to future periods. Forward-looking statements in this document include, but are not limited to, statements with respect to: the growth rate of the infant formula market; the projected market value of organic baby food worldwide in 2025; the number of countries for which patents will be granted; the characteristics of Else's potential product portfolio; the completion of Pre-Production scale up runs and the timing thereof; the completion of first commercial production and the timing thereof; the launch of a new website and e-store and the timing thereof; the creation of the new product lines in the Functional Foods and Whole Meal Snacks product categories, and the depictions

and descriptions of such products; the completion of Licensing Agreements for the Dairy Product Substitutes and Whole Meal Snacks product categories, and the depictions and descriptions of such underlying products; and the planned expansion into North American and international markets.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Furthermore, forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements, and the forward-looking statements are not guarantees of future performance.

Factors, assumptions and risks that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, consumer demand for Else's products, whether the Else current and future products achieve commercialization, including completing the scale up and, for certain products, regulatory approval, protecting the patents for the baby formula and further IP maintenance, receiving the necessary regulatory approvals to market and distribute the Else products, uncertainty regarding material changes in laws and regulations, including consumer protection and food regulations, retention of key personnel of Else involved in the production, testing and sale of the baby formula, the activities of competitors, and all related matters, including successful integration of the Golden Heart business, Else's ability to expand into global markets, general economic and political conditions and other more detailed risks, uncertainties and assumptions set out under the heading "Risk Factors" in Else's filing statement, which is available on [www.sedar.com](http://www.sedar.com) under the issuer profile of Else. Except as required by

law, Else disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on these forward-looking statements, and not to use this document as their sole source for decision making. Readers are encouraged to seek additional information and independent advice. This confidential presentation contains information that is subject to change without notice and is based on publicly available information, internally developed data, and information obtained by Else from third parties, including but not limited to market data and to the biographies of individuals serving as advisors to Else. Else believes such information to be accurate but has not independently verified such information. To the extent such information obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by Else based on such representations are not accurate. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. Else disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this confidential presentation, its accuracy, completeness or by reason of reliance by any person on any of it. This confidential presentation should not be construed as legal, financial or tax advice to any individual. The information contained in this confidential presentation is not directed to persons or entities resident in the United States and does not constitute an offer or solicitation by anyone in the United States or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation, unless otherwise exempt from United States securities legislation. Any forward-looking statement made in this confidential presentation, including orally, is based only on information currently available as of the date on which it is made.





## Baby Nutrition. Reimagined.

We stand with parents and families who demand a change in the baby and toddler nutrition industry.

Only now, we're doing more than just standing with you. We're changing things for you. Giving you a real choice. A choice that meets the gold standard for nutrition – and your standards for a clean label.

Much more than nutrition. **IT'S SOMETHING ELSE.**





# A BREAKTHROUGH, CLEAN-LABEL ALTERNATIVE TO DAIRY-BASED NUTRITION

Creating a Sustainable Plant-Based  
Alternative for an **\$US80 Billion**  
Global Infant Formula Market,  
Growing at a **CAGR of 5.58%** a Year,  
May Reach **\$US99 Billion** by 2024\*

*\*MarketWatch 2018-2024 forecast*





# AT A GLANCE – AUG 2020 US LAUNCH

## A Game Changer in Baby Nutrition

- The first 100% plant based non-dairy and non-soy formula alternative
- Nutritional equivalent to breast milk; essential amino acid & fatty acids profile
- Made from 3 plants - Almonds, Buckwheat and Tapioca
- 100% organic, vegan, natural and gluten-free
- Cleanest label, all natural and minimally processed
- Sustainable with minor ecological footprint

## Well Capitalized

- Publicly traded in the Toronto Stock Exchange – Venture (TSX-V)
- CAD\$**7.5M** raised in June 2019; RTO round led by Canaccord Genuity
- CAD\$**8M** raised in Feb 2020; led by the H&H Group, a Hong Kong based strategic investor
- CAD\$**25M** round will close in early Oct 2020, led by the H&H Group & Canaccord Genuity
- CAD\$**6.5M** in the treasury (EOM Aug 2020); with new investment - 18+ months operations
- 15 Employees; based in Tel Aviv, Israel. Holding company based in Vancouver Canada.



TSXV: **BABY**



OTCQX: **BABYF**



FSE: **OYL**

# FOUNDERS



**HAMUTAL YITZHAK**

**Co-Founder, Director & CEO**

Former Head of Infant Nutrition at  
Abbott labs Israel

Founder & Partner in Golden Heart  
baby snack co.



**MICHAEL AZAR**

**Co-Founder & CTO**

Former CEO & Chief Food  
Technologist at Materna (acquired  
by Nestle)

Infant Nutrition production expert



**URIEL KESLER**

**Co-Founder, Director & COO**

Former GM PL Infant Formula at  
Promedico Healthcare Group,  
Israel

Founder & Partner in Golden Heart  
baby snack co.



# TEAM



**Reuben Halevi**

**VP Sales Operation**

Former senior exec  
at Retalix®  
(NASDAQ:RTLX;  
acquired by NCR, 2012);  
Retail, technology,  
eCommerce &  
marketing expert



**Shay Shamir**

**CFO & Company  
Secretary**

Former CFO at  
Atlantium  
Technologies, Past  
roles at SuperCom and  
Ernst & Young.  
BA Accounting, CPA,  
MBA



**Barak Orenstein**

**Director Digital  
Marketing**

Former CMO at  
AHAVA, past Global  
Brand Director at  
Sodastream,  
L'Oreal & Danone,  
15+ years of FMCG



**Dr. Fabiana  
Bar-Yoseph**

**Director Clinical &  
Regulatory Affairs**

Former Clinical  
Development Director  
& Infant Nutrition R&D  
Director at Enzymotec,  
PhD in Medical Science



**Asher Widberg**

**Director New Product  
Development**

Former Head of Process  
Development - Infant  
Nutrition at Enzymotec.  
BSc in Bio-Chemical  
Engineering, MBA.



# TEAM

## Board Of Directors

- Hamutal Yitzhak ..... Founder, CEO & Director
- Uriel Kesler ..... Founder, COO & Director
- Sokhie Puar ..... Director
- Satwinder Mann ..... Director
- Eli Ronen ..... Director
- Akash Bedi ..... Director



## Advisory Board

- **Dr. Jon A Vanderhoof**  
Former Vice President, Global Medical Affairs at Mead Johnson Nutrition. Pediatric Gastroenterologist at Boston Children's Hospital, Senior Lecturer in Pediatrics at Harvard Medical School, USA
- **Prof. Ra'anan Shamir**  
Professor of Pediatrics, Sackler Faculty of Medicine, Tel-Aviv University. Chairman, Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center, Israel. Past President of ESPGHAN – European Society for Pediatric Gastroenterology Hepatology and Nutrition.
- **Katie Kaswell**  
Former Vice President of Marketing at Plum Organics Baby Foods, Formula and Snacks. Health-Supportive Chef.
- **Prof. Ron Shaoul**  
Head of Pediatric Gastroenterology and Nutrition Institute, RAMBAM Medical Center, Haifa, Israel, Clinical Associate Professor, Technion, Faculty of Medicine, Israel
- **Prof. Yvan Vandenplas**  
Head of Department KidZ Health Castle and Child Gastroenterology and Nutrition, Vrije University Hospital Brussels, Belgium

# THE CHALLENGE

**Infant Formula must meet  
the breast-milk nutritional gold standard**

**01**

Full essential  
amino acid  
profile ratio

**02**

Essential  
fatty acids  
profile ratio

**03**

Exact  
macronutrients  
ratio per 100kcal

# CURRENT STATE



- A strong allergen
- High levels of antibiotics, hormones and pesticides
- Animal welfare and other major environmental issues




- Controversial and declining GMO (99%)
- Proven allergen
- Chemically extracted Protein
- Suspected to have harmful effects on infants due to high levels of phytoestrogens (phytic hormones)




# ORGANIC FORMULA MARKET GROWING RAPIDLY



Market value of organic baby food worldwide in 2016  
and 2025 (in billion U.S dollars)  
Global organic baby food market size 2016-2025



# SPECIALTY IS A GROWTH MARKET



\* US market data Euromonitor 2019

# THE ALLERGY FACTS

**50%**

of US infants with food allergies are **allergic to cow's milk.**



**50%**

of babies allergic to cow's milk are also **allergic to Soy.**

\*Presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, Nov 2018





# THE SOLUTION

We have patented  
the world's first  
**100% Plant-based,  
Non-Dairy, Non-Soy**  
Baby Formula.



# THE FORMULA

We have achieved the strict nutritional composition of a “Formula” using a paradigm shifting method of processing the ingredients.



- ✓ All natural
- ✓ Based on 3 plants: almond, buckwheat & tapioca
- ✓ Cleanest Label
- ✓ Organic
- ✓ Free of hormones, antibiotics, gluten, Hexane, GMO
- ✓ Sustainable: minor ecological footprint
- ✓ Full Amino Acids profile and essential Fatty Acids
- ✓ Added natural carbohydrate

# DISRUPTIVE PROCESS

## Beyond Organic.

Transforming 3 plants in an all-natural process to a Breast Milk Nutritional Values Analog.

**92%** of our formula is made from three core ingredients.



almonds



tapioca



buckwheat



## Complete Nutrition. No Chemicals. And No Compromise.

We use a clean, all-natural process that allows us to break down our organic ingredients into water-soluble form, while still retaining their valuable nutrients.

## *In a nutshell:* We never alter the chemistry of the plant, just the texture.

Our production process is the cleanest and most natural in our industry. Why does that matter? Because whole foods (i.e.: less processed) contain more macro and micronutrients than their broken down, isolated components.

### what we left out:

- No protein isolates, highly-processed extracts, isolated single amino acids or GMO ingredients
- No use of hydrogenated external oil blends
- No chemicals
- No highly-processed ingredients

### what we left in:

- Real whole foods (almonds & buckwheat) in their natural composition
- All of the protein, fat and carbohydrates to support growth and development
- Phytonutrients, fiber, vitamins and minerals are more abundant when consumed as part of a whole food



# PATENTS

## Granted patents for the infant and toddler applications

USA	Japan	Mexico
Australia	New Zealand	South Africa
Eurasia (8 countries)	Israel	Chile
Ukraine	India	Korea

## Granted patents for the adult applications

Eurasia (8 countries)	New Zealand	Israel
USA	South Africa	
Ukraine	Japan	

## Pending patents applications (infants and Adults)

Australia	USA	Korea
Brazil	Israel	Canada
China	Mexico	
Europe (37 countries)		

**Composition based patent  
provides strongest protection**



\*Additional patent applications are being filed to protect new recent developments and innovations

# STATUS

## R&D, Production, Sales & Marketing Status



R&D for toddler & Children nutrition products is done  
FDA regulatory & clinical studies process for Infants started  
Liquid (RTD), adult nutrition and 6M+ baby food products in development



Pre-Production scaleup completed  
Samples are offered on e-store  
2 commercial production runs performed in July & Aug 2020  
Else e-store launched in Aug  
Amazon.com store launched in Sep  
5 retail brokers hired to cover US natural food & grocery chains and independent stores  
Product expected on shelves in Q4



US market research completed  
Brand strategy completed  
New website and e-store launched Q1 2020  
Social, Brand Ambassador, Influencers & Amazon digital marketing campaigns launched in Sep  
Hero overarching campaign to be launched in October



# EARLY ADOPTERS

A **Great Solution** for at least 40% of the US Market **NOW**

A **Viable Alternative** for everybody  
in the **long run**



**PROGRESSIVES  
HEALTH SEEKERS**



**ALLERGIC  
& SENSITIVE**



**VEGAN  
VEGETARIAN  
FLEXITARIAN**

**Plant  
Based**



**Whole  
Balanced  
Meal**



**Clean  
Label**



**Organic**



# THE FUTURE



# THE FUTURE ELSE NUTRITION

Else  
Young

- Infants
- Toddlers
- Kids

Else  
Complete

- Healthy Adults

Else  
Sensitive

- Adults with  
Special Dietary  
Requirements

# ELSE YOUNG



**POWDER**



**PUDDINGS**



**LIQUID (DRINKS)**



**CHIPS**



**SNACKS**



# ELSE COMPLETE



**BAKERY GOODS**



**SNACKS**



**MEAT/CHICKEN  
REPLACEMENTS**



**PLANT BASED  
WHOLE MEAL  
CHEESE**



**POWDER**





# ELSE SENSITIVE



TREATS



SNACKS



LIQUID (DRINKS)



PASTA



VEGAN YOGURT





# AS SEEN IN



[israeli-startup-shakes-up-the-formula-market-with-plant-based-milk](#)



[Else Nutrition Offers Clean-Ingredient, Plant-Based Toddler Formulas](#)



[Plant-based Baby Formula to Launch](#)



[Else Nutrition Launches Plant-based Toddler Formula](#)



[Else Nutrition to Disrupt Baby and Child Nutrition Forever as First Plant-Based Infant Formula Launches to Market](#)



[Else Nutrition Unveils Plant-based Toddler Milk Amid Broader Tensions in Formula Space](#)



[Else Nutrition Launches Plant-Based, Non-Dairy, Non-Soy Formulas](#)



[Alternatives to Traditional Infant Nutrition Hit US Market](#)



[Else Nutrition Launches Plant-Based Toddler Formula](#)



[Plant-based Toddler Formula Comes to Market](#)




[Hi-Tech Start-up to Launch Non-Soy Vegan Baby Formula](#)

# MARKET INFO

Share Capital Structure	September 30, 2020	October 2020*
Issued and Outstanding	80,685,996	92,108,552
Founders + Key person Warrants	32,401,489	32,401,489
Service Providers Warrants	6,200,000	6,200,000
Broker Warrants	919,062	1,517,022
Financing Warrants	3,066,227	8,777,505
Options Plan Pool	8,068,600	9,210,855
Fully Diluted	131,341,374	150,215,422

\*To be closed early Oct 2020




Symbols:

**TSX-V: BABY**

**OTCQX: BABYF**

**FSE: OYL**



52 weeks:

**\$0.28-\$3.40 CAD**





HAMUTAL YITZHAK  
Co-Founder, Director & CEO  
[hamutaly@elsenutrition.com](mailto:hamutaly@elsenutrition.com)

Investor Relations: [info@elsenutrition.com](mailto:info@elsenutrition.com)